Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 4.81% is in line with its 5-year average of 5.00%, near the low end of its 5-year range (2.67%–12.79%).
0.85% below its 12-month average of 4.85%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 3.54%.
NET PROFIT MARGIN
4.81%
NET PROFIT MARGIN AVG TTM
4.85%
NET PROFIT MARGIN AVG 3Y
5.11%
NET PROFIT MARGIN AVG 5Y
5.00%
NET PROFIT MARGIN AVG 10Y
8.66%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.85%
CURRENT VS 3Y AVG
-5.93%
CURRENT VS 5Y AVG
-3.75%
CURRENT VS 10Y AVG
-44.43%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+1474.29%
vs the sector median at left
Viemed Healthcare, Inc.
Market Cap
$355.36M
Net Profit Margin
4.81%
TTM Avg
4.85%
3Y Avg
5.11%
5Y Avg
5.00%
Market Cap
$355.43M
Net Profit Margin
0.00%
TTM Avg
-11651.99%
3Y Avg
-6142.69%
5Y Avg
-4693.07%
Market Cap
$353.88M
Net Profit Margin
-96.89%
TTM Avg
-148.47%
3Y Avg
-151.80%
5Y Avg
-119.69%
Market Cap
$352.67M
Net Profit Margin
-1786.27%
TTM Avg
-1435.22%
3Y Avg
-1851.09%
5Y Avg
-9692.20%
Market Cap
$359.53M
Net Profit Margin
-5.49%
TTM Avg
-11.37%
3Y Avg
-410.78%
5Y Avg
-2049.25%
Market Cap
$349.70M
Net Profit Margin
-184.60%
TTM Avg
-1235.34%
3Y Avg
-1300.41%
5Y Avg
-438.85%
Market Cap
$361.64M
Net Profit Margin
-1091.82%
TTM Avg
-436.37%
3Y Avg
-220.06%
5Y Avg
-1750.93%
Market Cap
$346.73M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viemed Healthcare, Inc. (VMD) | $355.36M | 4.81% | 4.85% | 5.11% | 5.00% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | 0.00% | -11651.99% | -6142.69% | -4693.07% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | -96.89% | -148.47% | -151.80% | -119.69% |
| Embecta Corp. (EMBC)vs › | $353.00M | 8.59% | 7.90% | 10.47% | 19.48% |
| Ocugen, Inc. (OCGN)vs › | $352.67M | -1786.27% | -1435.22% | -1851.09% | -9692.20% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | -5.49% | -11.37% | -410.78% | -2049.25% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | -184.60% | -1235.34% | -1300.41% | -438.85% |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | -1091.82% | -436.37% | -220.06% | -1750.93% |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | 0.00% | 0.00% | 0.00% | 0.00% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
8.1%
Net Profit Margin
4.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 3.54% |
| 2026-03-31 | 3.42% |
| 2025-12-31 | 7.40% |
| 2025-09-30 | 4.89% |
| 2025-06-30 | 5.01% |
| 2025-03-31 | 4.44% |
| 2024-12-31 | 7.11% |
| 2024-09-30 | 6.69% |
| 2024-06-30 | 2.67% |
| 2024-03-31 | 3.17% |
| 2023-12-31 | 6.85% |
| 2023-09-30 | 5.91% |
| 2023-06-30 | 5.38% |
| 2023-03-31 | 3.84% |
| 2022-12-31 | 6.50% |
| 2022-09-30 | 2.95% |
| 2022-06-30 | 2.90% |
| 2022-03-31 | 5.46% |
| 2021-12-31 | 12.79% |
| 2021-09-30 | 6.11% |
| 2021-06-30 | 5.72% |
| 2021-03-31 | 5.93% |
| 2020-12-31 | 16.25% |
| 2020-09-30 | 8.38% |
| 2020-06-30 | 45.30% |
| 2020-03-31 | 17.82% |
| 2019-12-31 | 17.38% |
| 2019-09-30 | 14.53% |
| 2019-06-30 | 8.95% |
| 2019-03-31 | 10.81% |
| 2018-12-31 | 16.47% |
| 2018-09-30 | 14.12% |
| 2018-06-30 | 15.26% |
| 2018-03-31 | 16.59% |
| 2017-12-31 | -0.19% |
| 2017-09-30 | 32.27% |
| 2017-06-30 | 16.26% |
| 2017-03-31 | 24.04% |
| 2016-12-31 | 32.51% |
| 2016-09-30 | 4.90% |
